infect
caus
antimicrobialresist
amr
bacteri
pathogen
increas
threat
public
health
ongo
amr
epidem
fuel
part
empir
broadspectrum
antibiot
therapi
led
explor
pathogenspecif
method
includ
use
monoclon
antibodi
mab
prevent
treat
seriou
bacteri
infect
numer
mab
current
develop
prevent
treatment
antibioticresist
bacteri
infect
passiv
immun
strategi
provid
immedi
potent
igg
respons
target
pathogen
ideal
mab
mab
cocktail
provid
multipl
mechan
action
neutral
key
bacteri
virul
factor
augment
host
innat
immun
respons
thu
provid
greatest
opportun
clinic
success
staphylococcu
aureu
bacteri
pathogen
caus
wide
array
diseas
includ
skin
softtissu
infect
endocard
osteomyel
pneumonia
bacteremia
preclin
result
indic
mabbas
approach
hold
promis
prophylaxi
adjunct
therapi
aureu
infect
previous
report
prophylaxi
multimechanist
mab
combin
target
alphatoxin
clump
factor
clfa
provid
enhanc
protect
improv
strain
coverag
rel
individu
mab
aureu
lethal
bacteremia
model
mab
combin
provid
multipl
mechan
action
includ
toxin
neutral
opsonophagocyt
kill
inhibit
fibrinogen
bind
bacteri
agglutin
similarli
mab
combin
target
pseudomona
aeruginosa
exopolysaccharid
psl
type
secret
system
compon
pcrv
provid
enhanc
protect
rel
individu
mab
p
aeruginosa
acut
pneumonia
model
mediat
opsonophagocyt
kill
opk
block
cell
attach
inhibit
inject
multipl
virul
factor
target
cell
two
exampl
provid
support
multimechanist
mabbas
antibacteri
treatment
approach
altern
approach
mab
combin
engin
bind
specif
singl
bispecif
bi
multispecif
igg
molecul
first
bi
antibodi
bisab
gener
somat
hybrid
two
antibodysecret
cell
produc
poor
yield
due
random
assembl
parent
heavi
light
chain
discoveri
singlechain
variabl
fragment
scfv
advanc
antibodi
engin
open
new
avenu
develop
bi
molecul
least
differ
bisab
format
base
scfv
number
fusion
posit
igg
scaffold
one
clear
mechanist
advantag
bisab
aris
bind
one
specif
facilit
bind
activ
second
specif
observ
bisab
target
p
aeruginosa
cell
surfac
exopolysaccharid
psl
tip
type
secret
system
injectisom
pcrv
antipsl
scfv
engin
hing
region
antipcrv
interestingli
construct
provid
enhanc
protect
rel
mab
combin
p
aeruginosa
acut
pneumonia
model
improv
activ
hypothes
result
highavid
loweraffin
bind
abund
psl
polysaccharid
around
bacterium
effect
increas
concentr
higheraffin
antipcrv
mab
around
cell
base
result
hypothes
highaffin
bind
bisab
compris
bind
specif
clfa
alphatoxin
could
increas
protect
capac
mab
combin
local
antialphatoxin
specif
bacteri
surfac
better
enabl
bisab
neutral
toxin
upon
secret
gener
variou
bisab
contain
antialphatoxin
anticlfa
activ
determin
anticlfa
mab
exhibit
poor
bind
affin
predomin
clfa
sequenc
type
consequ
gener
new
anticlfa
mab
increas
affin
three
main
clfa
sequenc
type
anticlfa
plu
antialphatoxin
bi
molecul
compris
antialphatoxin
rel
potenc
compar
vitro
vivo
although
bi
molecul
construct
retain
vitro
potenc
parent
mab
bi
molecul
construct
higheraffin
anticlfa
mab
exhibit
reduc
protect
activ
vivo
rel
mab
combin
aureu
pneumonia
bacteremia
model
contrast
vivo
activ
bisab
compar
observ
respect
mab
combin
interestingli
protect
activ
evid
mice
challeng
isogen
mutant
defect
clfa
express
suggest
highaffin
bind
clfa
bi
molecul
sequest
bacteri
surfac
therebi
prevent
alphatoxin
neutral
result
indic
bisab
approach
alway
superior
mab
combin
appropri
platform
select
requir
rigor
preclin
studi
relev
anim
model
previous
report
enhanc
protect
capac
isol
coverag
afford
prophylaxi
anti
aureu
alphatoxin
mab
combin
anticlfa
mab
rel
individu
mab
aureu
lethal
bacteremia
model
although
potent
anticlfa
mab
found
exhibit
reduc
affin
kon
limit
detect
nd
tabl
increas
inhibitori
concentr
fibrinogen
bind
inhibit
assay
rel
fig
tabl
express
promin
aureu
hospitalacquir
methicillinresist
aureu
hamrsa
sequenc
type
strain
increas
potenti
clinic
isol
coverag
screen
human
tonsillar
b
cell
search
broadli
reactiv
anticlfa
mab
effort
identifi
mab
high
affin
appar
dissoci
constant
kd
pm
tabl
potent
inhibit
fibrinogen
bind
promin
clfa
genotyp
fig
also
exhibit
opsonophagocyt
kill
opk
activ
sever
aureu
clinic
isol
see
fig
supplement
materi
improv
inhibit
bacteri
agglutin
human
plasma
compar
fig
fig
found
compet
bind
enzymelink
immunosorb
assay
elisa
octetbas
competit
assay
fig
b
result
indic
mab
bind
overlap
epitop
suggest
potenc
differ
result
differ
bind
affin
protect
activ
next
evalu
murin
lethal
bacteremia
model
alon
combin
mgkg
prophylaxi
result
increas
surviv
compar
isotyp
control
igg
cigg
follow
challeng
aureu
isol
repres
confirm
encod
clfa
genotyp
respect
tabl
fig
similar
prophylaxi
combin
mgkg
significantli
increas
surviv
rel
cigg
follow
challeng
strain
test
provid
benefit
individu
mab
strain
tabl
result
indic
function
vivo
confirm
need
mab
combin
provid
broader
strain
coverag
passiv
immun
mab
combin
provid
benefit
strain
coverag
lethal
bacteremia
retain
antialphatoxin
protect
capac
murin
dermonecrosi
pneumonia
model
determin
bisab
compris
anticlfa
antialphatoxin
mab
provid
benefit
mab
combin
engin
bisab
compris
igg
backbon
scfv
append
amino
carboxi
terminu
heavi
chain
fig
format
select
scfv
locat
dispar
locat
igg
way
determin
one
format
advantag
anoth
test
empir
antibodi
specif
interest
understand
bisab
retain
function
activ
individu
mab
measur
potenc
inhibit
alphatoxindepend
rabbit
red
blood
cell
rbc
lysi
inhibit
fibrinogen
bind
molecul
exhibit
similar
alphatoxin
hemolyt
assay
wherea
exhibit
reduc
alphatoxin
neutral
activ
fig
tabl
bisab
exhibit
similar
respect
parent
anticlfa
igg
fibrinogen
bind
inhibit
assay
wherea
lost
activ
still
superior
fig
fig
tabl
bisab
also
mediat
opk
similar
parent
anticlfa
igg
fig
importantli
satur
antialphatoxin
scfv
presenc
excess
alphatoxin
interfer
anticlfa
activ
fibrinogen
bind
assay
fig
similarli
satur
clfa
bind
clfa
excess
decreas
alphatoxin
neutral
activ
bisab
hemolyt
assay
fig
tabl
taken
togeth
result
indic
bi
molecul
retain
vitro
function
activ
case
similar
parent
igg
activ
diminish
presenc
molar
excess
antigen
recogn
bisab
bisab
protect
activ
next
compar
mab
combin
aureu
lethal
bacteremia
model
mice
passiv
immun
mab
combin
mgkg
mgkg
equimolar
dose
bisab
mgkg
respect
h
prior
intraven
iv
infect
aureu
surviv
monitor
day
mgkg
exhibit
reduc
significantli
differ
p
p
protect
compar
mab
combin
mgkg
fig
mab
combin
mgkg
p
versu
cigg
mgkg
p
versu
cigg
significantli
increas
surviv
rel
cigg
consist
observ
loss
alphatoxin
neutral
activ
vitro
fig
significantli
increas
surviv
administ
mgkg
p
fig
test
aureu
strain
mrsa
strain
neither
mab
alon
suffici
signific
protect
fig
molecul
mgkg
significantli
increas
surviv
rel
cigg
p
wherea
equimolar
concentr
mgkg
mab
combin
p
versu
cigg
fig
suggest
defect
vivo
interestingli
passiv
immun
result
protect
similar
mab
combin
dose
mgkg
mgkg
provid
signific
increas
surviv
rel
cigg
strain
fig
result
indic
bisab
provid
benefit
mab
combin
previous
observ
p
aeruginosa
rather
convers
bi
exhibit
loss
protect
lower
dose
strain
individu
mab
suffici
provid
protect
sinc
mab
either
bi
format
bind
greater
affin
tabl
hypothes
bind
clfa
sequest
bisab
bacteri
surfac
lead
poorer
captur
neutral
alphatoxin
secret
alphatoxin
key
virul
factor
aureu
pneumonia
passiv
immun
antialphatoxin
mab
alon
protect
mice
lethal
aureu
pneumonia
moreov
previous
show
anticlfa
mab
impact
surviv
pneumonia
model
provid
protect
similar
antialphatoxin
alon
therefor
determin
decreas
protect
observ
lethal
bacteremia
model
result
inadequ
alphatoxin
neutral
examin
efficaci
lethal
pneumonia
model
passiv
immun
mgkg
alon
combin
result
protect
follow
challeng
howev
passiv
immun
result
surviv
respect
fig
interestingli
passiv
immun
reduc
affin
clfa
tabl
provid
surviv
result
support
conclus
bind
clfa
bacteri
surfac
sequest
thu
impair
alphatoxin
neutral
test
hypothesi
mice
passiv
immun
molecul
prior
intranas
infect
clfa
isogen
mutant
prophylaxi
provid
protect
mutant
similar
fig
result
provid
evid
bind
surfaceloc
clfa
prevent
effect
neutral
solubl
alphatoxin
aureu
possess
larg
arsen
secret
surfaceexpress
virul
factor
enabl
caus
wide
array
diseas
rang
mild
skin
softtissu
infect
sever
invas
diseas
pneumonia
osteomyel
bloodstream
infect
differenti
express
virul
factor
among
clinic
isol
differ
diseas
present
challeng
design
immunotherapeut
method
treatment
prophylaxi
may
respons
part
past
clinic
failur
target
individu
aureu
virul
determin
therefor
immunotherapeut
strategi
target
multipl
virul
pathway
may
block
multipl
pathogen
mechan
improv
diseas
coverag
increas
likelihood
clinic
success
although
alphatoxin
key
virul
determin
aureu
pneumonia
skin
softtissu
infect
bloodstream
infect
like
complex
complic
interplay
virul
determin
involv
consist
hypothesi
prophylaxi
antialphatoxin
igg
alon
significantli
reduc
diseas
sever
aureu
pneumonia
skin
infect
model
mice
rabbit
protect
challeng
isol
test
lethal
bacteremia
model
tabl
howev
passiv
immun
combin
anticlfa
mab
provid
improv
strain
coverag
indic
target
multipl
virul
factor
may
necessari
protect
system
aureu
diseas
bacteremia
tabl
fig
clfa
fibrinogenbind
cell
surfac
adhesin
mediat
bacteri
agglutin
attach
fibrinogenco
surfac
promot
complement
evas
despit
promis
preclin
anim
result
limit
number
strain
anticlfa
mab
tefibazumab
aurexi
intraven
immunoglobulin
ivig
enrich
high
anticlfa
titer
veron
fail
demonstr
protect
effect
clinic
test
may
result
target
singl
virul
factor
differenti
express
among
clinic
isol
clfa
sequenc
variat
inde
bradi
et
al
recent
report
clfa
sequencedepend
epitop
gener
antibodi
respons
follow
vaccin
reduc
affin
versu
anticlfa
mab
gener
test
bind
founder
clfa
sequenc
bound
similarli
exhibit
drop
affin
low
affin
result
loss
function
activ
fig
tabl
howev
find
translat
detect
loss
vivo
protect
strain
test
one
possibl
explan
result
highavid
bind
bacteri
surfac
compens
loss
mab
affin
clfa
nevertheless
sinc
strain
frequent
associ
bloodstream
infect
campaign
initi
identifi
broadli
reactiv
highaffin
anticlfa
mab
human
tonsillar
memori
b
cell
lead
mab
identifi
campaign
exhibit
least
greater
affin
founder
clfa
genotyp
tabl
improv
vitro
function
activ
fig
strain
fig
broad
strain
coverag
lethal
bacteremia
combin
antialphatoxin
mab
tabl
fig
benefit
mab
vaccin
antigen
combin
target
individu
antigen
also
report
pathogen
fact
shown
combin
mab
multipl
mechan
action
singl
bisab
provid
improv
protect
activ
individu
mab
also
mab
combin
addit
potenti
improv
efficaci
bisab
singlemolecul
approach
could
simplifi
ab
manufactur
eg
express
purif
overcom
regulatori
hurdl
associ
clinic
develop
mab
combin
bisab
except
lost
alphatoxinneutr
activ
exhibit
activ
vitro
similar
parent
mab
fig
b
howev
provid
benefit
mab
combin
vivo
bi
molecul
construct
higheraffin
anticlfa
mab
even
lost
protect
activ
rel
mab
combin
fig
b
result
alphatoxin
clfa
simpli
compet
bisab
bind
bisab
retain
full
activ
vitro
presenc
excess
either
clfa
alphatoxin
fig
vivo
activ
loss
like
result
highaffin
bind
clfa
sequest
bisab
bacteri
surfac
appar
less
effect
captur
neutral
alphatoxin
secret
conclus
support
find
retain
full
alphatoxin
neutral
activ
mice
infect
lack
clfa
fig
work
also
compar
activ
two
bi
construct
differ
antibodi
pair
target
antigen
bi
construct
differ
antialphatoxin
scfv
fuse
either
n
c
terminu
heavi
chain
molecul
retain
full
anticlfa
antialphatoxin
neutral
activ
altern
lost
alphatoxinneutr
activ
indic
bestperform
bi
molecul
case
independ
antigenspecif
scfv
locat
result
highlight
fact
igg
characterist
antigen
specif
affin
locat
distanc
fab
scfv
may
use
predict
bisab
activ
best
bi
format
must
select
empir
individu
igg
pair
exampl
antibacteri
bisab
p
aeruginosa
bind
abund
cell
surfac
polysaccharid
psl
pcrv
type
secret
system
like
combin
exhibit
multipl
mechan
action
includ
opsonophagocyt
kill
antiadher
activ
psl
inhibit
cytotox
contrast
bisab
exhibit
improv
neutral
activ
vitro
increas
protect
murin
pneumonia
model
rel
mab
combin
increas
potenc
hypothes
result
lowaffin
bind
highli
abund
surfac
polysaccharid
psl
therebi
increas
local
concentr
highaffin
bind
subsequ
neutral
lowabund
surfac
target
pcrv
bind
two
distinct
surfac
antigen
differenti
affin
like
account
improv
activ
seen
vitro
vivo
assay
compar
efficaci
differ
bi
molecul
antipcrv
mab
fab
antipsl
scfv
link
ntermin
ctermin
upper
hing
region
show
better
activ
construct
suggest
interparatop
distanc
import
activ
contrast
graft
either
n
terminu
c
terminu
molecul
bind
higher
affin
surfaceloc
clfa
like
sequest
bisab
bacteri
surfac
prevent
optim
neutral
alphatoxin
taken
togeth
result
support
rational
use
multimechanist
mab
strategi
provid
potent
broadli
protect
activ
aureu
bacteremia
howev
combin
anticlfa
antialphatoxin
bind
specif
one
bisab
demonstr
benefit
mab
mixtur
also
highaffin
anticlfa
mab
use
bi
show
reduc
vivo
activ
find
illustr
bispecif
approach
mab
combin
univers
appli
antibacteri
mab
combin
decis
use
mab
combin
bisab
like
depend
mani
factor
includ
antigen
locat
surfaceexpress
secret
antigen
concentr
densiti
rel
mab
compon
bind
affin
along
development
regulatori
concern
highlight
need
empir
determin
mab
format
independ
desir
applic
communityacquir
mrsa
isogen
clfa
delet
mutant
previous
describ
nr
strain
obtain
network
antimicrobi
resist
staphylococcu
aureu
narsa
arc
strain
obtain
astra
zeneca
research
collect
strain
identifi
number
begin
obtain
eurofin
strain
correspond
multilocu
sequenc
type
mlst
clfa
genotyp
summar
tabl
supplement
materi
dna
purifi
bacteri
cultur
via
bead
beat
follow
extract
use
purelink
genom
dna
minikit
thermofish
sequenc
librari
prepar
covari
mechan
shear
follow
nebnext
ultra
dna
librari
prepar
kit
illumina
new
england
biolab
inc
sequenc
perform
via
miseq
run
illumina
target
depth
read
de
novo
assembl
clcbio
genom
workbench
clfa
open
read
frame
extract
translat
protein
sequenc
clfa
protein
allel
present
studi
match
allel
number
murphi
et
al
compar
sequenc
studi
genbank
access
number
common
refer
mlst
determin
use
aureu
mlst
profil
http
pubmlstorg
memori
b
cell
isol
cryopreserv
lymphocyt
isol
tonsil
use
phycoerythrin
pe
microbead
bd
bioscienc
follow
stain
antip
bead
miltenyi
biotec
deplet
cell
carri
igm
igd
iga
cell
sort
facsaria
bd
bioscienc
cell
immort
clonal
condit
epsteinbarr
viru
describ
previous
week
cultur
supernat
screen
presenc
mab
use
elisa
posit
cultur
expand
complet
rpmi
medium
select
abil
bind
clfa
genotyp
high
affin
vh
vl
sequenc
retriev
revers
transcriptionpcr
rtpcr
clfa
sequenc
correspond
domain
amino
acid
clfa
genotyp
obtain
genbank
access
number
dna
encod
sequenc
codon
optim
subclon
avitag
biotinyl
signal
glndifeaqkiewh
clone
end
clfa
code
sequenc
express
escherichia
coli
biotinyl
induc
cotransform
cell
iptg
induc
plasmid
contain
bira
gene
encod
biotin
ligas
avitagclfa
contain
recombin
protein
purifi
e
coli
lysat
use
histrap
hp
column
ge
healthcar
equilibr
buffer
mm
sodium
phosphat
ph
mm
nacl
column
wash
buffer
follow
dimethylammonio
buffer
endotoxin
remov
impur
remov
mm
imidazol
teknova
wash
clfa
elut
linear
gradient
mm
imidazol
clfacontain
fraction
pool
dialyz
q
buffer
mm
tri
ph
lysat
load
onto
hitrap
q
sepharos
hp
column
ge
healthcar
elut
linear
gradient
mm
nacl
fraction
contain
pure
clfa
dialyz
phosphatebuff
salin
pb
ph
aliquot
frozen
bispecif
antibodi
gener
previous
describ
briefli
anticlfa
mab
use
igg
scaffold
graft
scfv
format
scfv
synthes
vlvh
format
linker
light
heavi
variabl
domain
geneart
life
technolog
il
construct
fuse
scfv
sequenc
n
terminu
heavi
chain
anticlfa
construct
gener
append
linkerscfv
c
terminu
heavi
chain
molecul
express
transient
transfect
cell
purifi
protein
affin
chromatographi
polish
size
exclus
chromatographi
integr
molecul
assess
mass
spectrophotometri
intact
mass
peptid
map
verifi
proper
format
engin
endogen
disulfid
bound
rabbit
red
blood
cell
rbc
hemolyt
assay
perform
describ
previous
briefli
serial
dilut
bisab
nm
mix
alphatoxin
nm
incub
wash
rabbit
rbc
peel
freez
h
assay
antialphatoxin
scfv
bisab
satur
excess
clfa
plate
centrifug
rpm
min
supernat
transfer
new
plate
nonspecif
human
use
neg
control
cigg
optic
densiti
nm
measur
spectrophotomet
molecular
devic
inhibit
hemolysi
calcul
odalphatoxinmabodalphatoxin
nunc
maxisorp
plate
thermo
fisher
scientif
coat
overnight
human
fibrinogen
sigma
wash
pb
contain
tween
wash
buffer
block
h
room
temperatur
rt
casein
thermo
fisher
follow
wash
plate
incub
h
room
temperatur
mix
avitag
serial
dilut
anticlfa
mab
bisab
final
volum
pb
assay
anticlfa
bisab
satur
excess
alphatoxin
mm
wash
bound
clfa
detect
use
horseradish
peroxidas
hrp
conjug
streptavidin
ge
healthcar
tmb
substrat
kpl
reaction
stop
min
plate
read
spectrophotomet
percent
inhibit
clfa
bind
fibrinogen
calcul
follow
formula
odclfamabodclfa
mab
aureu
clinic
isol
cultur
overnight
tryptic
soy
broth
wash
pb
suspend
onetenth
origin
volum
icecold
pb
anticlfa
mab
bisab
serial
dilut
pb
start
mix
citrat
human
plasma
ubottom
plate
thermo
fisher
scientif
bacteria
ad
incub
min
well
evalu
visual
lowest
mab
concentr
bacteria
agglutin
record
human
mab
util
isotyp
control
human
cigg
cell
obtain
atcc
manassa
va
opk
assay
conduct
previous
describ
kinet
rate
constant
kon
koff
bind
anticlfa
mab
clfa
genotyp
measur
use
igg
captur
assay
sensor
chip
final
surfac
densiti
reson
unit
ru
biacor
instrument
ge
healthcar
life
scienc
refer
flow
cell
surfac
also
prepar
sensor
chip
use
ident
immobil
protocol
without
mab
anticlfa
mab
prepar
nm
nm
immobil
buffer
mm
sodium
acet
ph
along
serial
dilut
clfa
nm
nm
nm
nm
instrument
buffer
hbsep
buffer
hepe
ph
nacl
mm
edta
concentr
clfa
first
inject
immobil
mab
refer
surfac
flow
rate
result
bind
respons
curv
yield
associ
phase
data
follow
inject
clfa
flow
switch
back
instrument
buffer
min
h
highest
concentr
permit
collect
dissoci
phase
data
follow
puls
mm
glycin
ph
regener
iggimmobil
surfac
chip
bind
respons
duplic
inject
concentr
clfa
record
mab
addit
sever
buffer
inject
interspers
throughout
inject
seri
select
buffer
inject
use
along
refer
cell
respons
correct
raw
data
set
inject
artifact
andor
nonspecif
bind
interact
fulli
correct
bind
data
fit
bind
model
biacor
evalu
softwar
version
biacor
inc
includ
term
correct
mass
transportlimit
bind
detect
analys
determin
kinet
rate
constant
kon
koff
appar
dissoci
constant
kd
calcul
koffkon
anticlfa
mab
test
competit
assay
bind
octet
system
briefli
mab
dilut
pb
captur
aminopropylsilan
ap
biosensor
min
coat
biosensor
move
block
buffercontain
well
pb
mgml
bovin
serum
albumin
sigma
min
block
free
sensor
bind
site
subsequ
incub
min
dilut
block
buffer
final
move
well
contain
compet
mab
dilut
block
buffer
data
analyz
use
octet
data
acquisit
analysi
softwar
absenc
associ
compet
mab
result
competit
thu
recognit
antigen
site
noncompetit
obtain
associ
second
mab
detect
experi
perform
accord
institut
guidelin
follow
experiment
protocol
review
approv
institut
biosafeti
committe
ibc
institut
anim
care
use
committe
iacuc
medimmun
group
femal
balbc
mice
harlan
passiv
immun
intraperiton
ip
inject
cigg
bi
molecul
anticlfa
combin
challeng
h
later
intraven
iv
inject
lethal
dose
aureu
isol
surviv
monitor
week
statist
analysi
specif
antistaphylococc
antigen
versu
cigg
perform
log
rank
mantelcox
test
data
consid
statist
differ
p
valu
indic
asterisk
femal
mice
jackson
inject
ip
bi
molecul
pneumonia
induc
intranas
infect
cfu
describ
previous
anim
surviv
monitor
day
statist
analysi
versu
cigg
perform
log
rank
mantelcox
test
data
consid
statist
differ
p
valu
indic
asterisk
